Nadifloxacin: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Acne vulgaris

Adult: As 1% cream/gel: Apply to affected area bid. Discontinue treatment if desired effect is not achieved after 4 weeks.

Contraindications

Hypersensitivity to nadifloxacin or other fluoroquinolones.

Adverse Reactions

Skin and subcutaneous tissue disorders: Itching and erythema at application sites, pruritus, redness, flushing, feeling of facial warmth, papules, contact dermatitis, dry skin.

Action

Description: Nadifloxacin, a synthetic fluoroquinolone anti-infective agent, acts by inhibiting the bacterial DNA gyrase which is involved in DNA synthesis and replication, thus inhibiting bacterial multiplication
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 8 hours (post-final dosing).
Excretion: Via urine (approx 0.09%). Elimination half-life: 19.4 hours.

Chemical Structure

Storage

Store below 30°C.

MIMS Class

Topical Antibiotics

ATC Classification

D10AF05 - nadifloxacin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.

References

Acuatim (Otsuka). MIMS Indonesia. http://mims.com/indonesia. Accessed 17/01/2020.

Anon. Nadifloxacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/01/2020.

Buckingham R (ed). Nadifloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/01/2020.

Nadibact (Cipla - Xterna). MIMS Philippines. http://mims.com/philippines. Accessed 17/01/2020.

Quinolones. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 17/01/2020.

Disclaimer: This information is independently developed by MIMS based on Nadifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com